Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron And Lilly Are Back With Better COVID-19 Antibody Data – But Still Face Medical Skepticism

New Variants Also Make SARS-CoV2 A Moving Target

Executive Summary

After disappointing initially, Lilly and Regeneron are back with compelling data for their monoclonal antibody products, but still face challenges from new COVID-19 variants and medical skepticism.

You may also be interested in...



Keeping Track: New Uses For Opdivo, Trodelvy; Nextstellis Introduces A Novel Estrogen

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Regeneron COVID-19 Antibody Poised To Add Prevention Claim, Sub-Q Formula

The company is requesting FDA expand the antibody cocktail to include a COVID prevention claim with a lower 1,200mg dose and a subcutaneously administered formula.

Can Vir/GSK’s COVID-19 Antibody Prove Its Worth In Early Disease?

Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel